technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using OMS ElectroImmunotherapy to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.
About Melanoma
Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable, but if it is not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths. The American Cancer Society estimates that at present, about 123,000 new cases of melanoma in the US are diagnosed in a year, resulting in approximately 10,000 deaths. Melanoma originates in melanocytes, the cells which produce the pigment melanin that colors our skin, hair, and eyes. The majority of melanomas are black or brown, but often they can also be skin-colored, pink, red, purple, blue or white. Currently, there remains few treatment options for patients with late stage metastatic disease that can extend survival for the broad population.
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently ava
'/>"/>
SOURCE OncoSec Medical Incorporated Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine technology :1.
OncoSec to Present at World Cancer Immunotherapy Conference2.
OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference3.
OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference4.
OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies5.
OncoSec to Present at Medical Device Investor Forum6.
Device Master File for OncoSec Medical System Completed and Submitted to FDA7.
OncoSec Releases Devices for Use in Clinical Trials8.
Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials9.
OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials10.
OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference11.
OncoSec Medical to Present at Industry and Investor Conferences